表面蛋白组学可实现胰腺癌患者液体活检中癌症特异性外泌体货物的分离
本研究对胰腺导管腺癌(PDAC)外泌体表面蛋白进行蛋白质组学分析,鉴定出CLDN4、EPCAM、CD151等候选标志物,并利用抗体混合物捕获PDAC特异性外泌体,使KRAS突变检出率从44.1%提升至73.0%,富集后的外泌体货物可用于下游分子分析。
要点
- PDAC外泌体表面蛋白组学鉴定出CLDN4、EPCAM、CD151、LGALS3BP、HIST2H2BE、HIST2H2BF等候选标志物。
- 在治疗中患者中,总外泌体KRAS突变检出率为44.1%,经所选标志物捕获后为73.0%。
- 富集的外泌体货物可用于分子分析,在一例BRCA2突变患者中阐明了PARP抑制剂耐药的推定机制。
核心结论
- 外泌体为液体活检中富集循环肿瘤特异性物质提供了独特机会。
- 本研究对PDAC外泌体进行了全面的表面蛋白组学表征,可实现肿瘤来源DNA的捕获和分子分析。
研究设计与样本
- 研究对13种人PDAC细胞系和2种非肿瘤细胞系的外泌体表面蛋白进行液相色谱-质谱联用分析。
- 前瞻性收集103例PDAC患者的173份血液样本进行外泌体分离。
- 对74例患者(共136份外泌体样本)使用微滴式数字PCR检测治疗期间的基线KRAS突变检出率。
- 对另外29例患者(37份样本)使用针对所选蛋白的抗体混合物进行PDAC特异性外泌体捕获,随后进行微滴式数字PCR分析。
- 对一例治疗耐药的PDAC患者使用分子条形码靶向测序面板分析外泌体DNA。
主要发现
- 外泌体表面蛋白组学分析揭示了多个PDAC特异性候选生物标志物:CLDN4、EPCAM、CD151、LGALS3BP、HIST2H2BE和HIST2H2BF。
- 在治疗中患者中,总外泌体KRAS突变检出率为44.1%,而使用所选生物标志物捕获外泌体后KRAS突变检出率为73.0%。
- 外泌体货物富集后适用于分子分析,在一例携带BRCA2突变的患者中阐明了PARP抑制剂治疗的推定耐药机制。
关键数值与推荐
- PDAC特异性外泌体捕获使用针对CLDN4、EPCAM、CD151、LGALS3BP、HIST2H2BE和HIST2H2BF的抗体混合物。
- 总外泌体KRAS突变检出率44.1% vs 捕获后73.0%(捕获后较总外泌体升高)。
- KRAS突变检测使用微滴式数字PCR。
临床怎么用
- 外泌体表面蛋白组学可鉴定PDAC特异性标志物,用于液体活检中肿瘤来源外泌体的富集。
- 基于所选标志物的外泌体捕获可提高治疗中PDAC患者KRAS突变的检出率。
- 富集的外泌体货物可用于下游分子分析,包括耐药机制的探究。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Detection of circulating tumor DNA can be limited due to their relative scarcity in circulation, particularly while patients are actively undergoing therapy. Exosomes provide a vehicle through which cancer-specific material can be enriched from the compendium of circulating non-neoplastic tissue-derived nucleic acids. We carried out a comprehensive profiling of the pancreatic ductal adenocarcinoma (PDAC) exosomal 'surfaceome' in order to identify surface proteins that will render liquid biopsies amenable to cancer-derived exosome enrichment for downstream molecular profiling. PATIENTS AND METHODS: Surface exosomal proteins were profiled in 13 human PDAC and 2 non-neoplastic cell lines by liquid chromatography-mass spectrometry. A total of 173 prospectively collected blood samples from 103 PDAC patients underwent exosome isolation. Droplet digital PCR was used on 74 patients (136 total exosome samples) to determine baseline KRAS mutation call rates while patients were on therapy. PDAC-specific exosome capture was then carried out on additional 29 patients (37 samples) using an antibody cocktail directed against selected proteins, followed by droplet digital PCR analysis. Exosomal DNA in a PDAC patient resistant to therapy were profiled using a molecular barcoded, targeted sequencing panel to determine the utility of enriched nucleic acid material for comprehensive molecular analysis. RESULTS: Proteomic analysis of the exosome 'surfaceome' revealed multiple PDAC-specific biomarker candidates: CLDN4, EPCAM, CD151, LGALS3BP, HIST2H2BE, and HIST2H2BF. KRAS mutations in total exosomes were detected in 44.1% of patients undergoing active therapy compared with 73.0% following exosome capture using the selected biomarkers. Enrichment of exosomal cargo was amenable to molecular profiling, elucidating a putative mechanism of resistance to PARP inhibitor therapy in a patient harboring a BRCA2 mutation. CONCLUSION: Exosomes provide unique opportunities in the context of liquid biopsies for enrichment of tumor-specific material in circulation. We present a comprehensive surfaceome characterization of PDAC exosomes which allows for capture and molecular profiling of tumor-derived DNA.
引用
- Castillo J, Bernard V, San Lucas FA, et al. Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients. Ann Oncol. 2018. PMID: 29045505. doi:10.1093/annonc/mdx542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。